Drug intelligence / Profile preview

TTI-0102

Development stage
Unknown
Lead developer
Thiogenesis Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

TTI-0102 is an investigational small molecule cysteamine precursor being developed by the VA Office of Research and Development. It is currently under evaluation as an adjunct therapy to Compensatory Cognitive Training (CCT) for Veterans suffering from mild to moderate traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD). The drug exhibits anti-inflammatory activity and is hypothesized to address chronic TBI symptoms by mitigating neuroinflammation, improving brain energy production, and potentially repairing blood-brain barrier permeability. Clinical studies are investigating its mechanism of action through biological profiling of inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP), as well as brain-derived neurotrophic factor (BDNF).

Other names
Cysteamine precursor
02

Targets

BDNF (Brain-derived neurotrophic factor)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on TTI-0102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTI-0102.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call